Table 3 HPV-16, -18 and -58 prevalence, viral load and physical status in patients with ESCC and CSCC, and in their corresponding controls

HPV16

>0.86

0. 10-0.86

0.001-0.10

<0.001

ESCC

70

21(30.00)

0.02-9.28

2.19 ± 2.60

0.25 ± 0.37

2

5

8

6

NE

60

13(21.67)

0.04-2.08

0.55 ± 0.16

0.51 ± 0.36

3

7

2

1

CSCC

39

19(48.72)

32.03-1546.38

468.39 ± 473.36

0.03 ± 0.08

0

5

5

9

NC

54

8(14.81)

0.12-122.92

26.21 ± 34.26

0.59 ± 0.44

4

3

1

0

HPV18

>0.82

0. 10-0.82

0.00-0.10

<0.001

ESCC

70

8(11.43)

0.00-11.29

2.03 ± 3.88

0.17 ± 0.14

0

1

6

1

NE

60

3(2.00)

0.03-2.25

0.73 ± 1.26

0.37 ± 0.14

0

2

0

1

CSCC

39

7(17.95)

5.14-295.38

174.77 ± 121.20

0.06 ± 0.10

0

2

3

2

NC

54

2(3.70)

1.22-130.51

65.87 ± 91.42

0.60 ± 0.34

1

1

0

0

HPV58

>0.78

0. 10-0.78

0.001-0.10

<0.001

ESCC

70

9(21.43)

0.03-12.56

3.86 ± 3.82

0.17 ± 0.32

1

1

3

4

NE

60

4(6.67)

0.17-2.65

1.68 ± 1.09

0.35 ± 0.31

0

3

1

0

CSCC

39

9(23.08)

4.11-1521.70

280.27 ± 499.13

0.12 ± 0.18

0

3

0

6

NC

54

2(3.70)

0.99-106.59

53.79 ± 74.67

0.64 ± 0.26

1

1

0

0

3 HR-HPVs

ESCC

70

35(50.00)

0.00-12.56

2.55 ± 3.19 ^a

0.20 ± 0.32

3

6

16

10^d

NE

60

20(33.33)

0.04-2.08

0.55 ± 0.57

0.53 ± 0.33

3

12

3

2

CSCC

39

31(79.48)

4.11-1546.38

361.29 ± 441.75^bc

0.09 ± 0.14

0

9

6

16^{e f}

NC

54

10(18.52)

0.12-853.43

30.87 ± 57.39

0.55 ± 0.40

6

3

1

0